Opsynvi, macitentan and tadalafil
Named-patient access overview. Opsynvi is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Opsynvi
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Opsynvi
Opsynvi (macitentan and tadalafil) is manufactured by Janssen and indicated for Pulmonary arterial hypertension (WHO group 1). It is an oral fixed-dose combination (endothelin receptor antagonist + PDE5 inhibitor) approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Opsynvi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Opsynvi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Opsynvi is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. If you are pursuing Opsynvi for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Opsynvi is in our coordination scope. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Opsynvi
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.